{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T20:01:45Z","timestamp":1774641705877,"version":"3.50.1"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100007747","name":"Red Espa\u00f1ola de Esclerosis M\u00faltiple","doi-asserted-by":"publisher","award":["16\/0015\/0002"],"award-info":[{"award-number":["16\/0015\/0002"]}],"id":[{"id":"10.13039\/501100007747","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Instituto de Salud Carlos III-Subdirecci\u00f3n General de Evaluaci\u00f3n"},{"DOI":"10.13039\/501100008530","name":"Fondo Europeo de Desarrollo Regional","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010552","name":"Departament de Salut de la Generalitat de Catalunya","doi-asserted-by":"crossref","award":["SLT002\/16\/00354"],"award-info":[{"award-number":["SLT002\/16\/00354"]}],"id":[{"id":"10.13039\/501100010552","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["JR16\/00006"],"award-info":[{"award-number":["JR16\/00006"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["JR17\/00012"],"award-info":[{"award-number":["JR17\/00012"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["CM16\/00136"],"award-info":[{"award-number":["CM16\/00136"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.msard.2019.101483","type":"journal-article","created":{"date-parts":[[2019,11,3]],"date-time":"2019-11-03T08:49:39Z","timestamp":1572770979000},"page":"101483","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"special_numbering":"C","title":["Rebound of multiple sclerosis activity after fingolimod withdrawal due to planning pregnancy: Analysis of predisposing factors"],"prefix":"10.1016","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3078-645X","authenticated-orcid":false,"given":"Maria","family":"Sep\u00falveda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmen","family":"Montejo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Llufriu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6396-219X","authenticated-orcid":false,"given":"Nuria","family":"Sola-Valls","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Reyes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena H.","family":"Martinez-Lapiscina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irati","family":"Zubizarreta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irene","family":"Pulido-Valdeolivas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eugenia","family":"Martinez-Hernandez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helena","family":"Ari\u00f1o","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nuria","family":"Ba\u00f1os","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Albert","family":"Saiz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1834-0498","authenticated-orcid":false,"given":"Yolanda","family":"Blanco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2019.101483_bib0001","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1056\/NEJM199807303390501","article-title":"Rate of pregnancy-related relapse in multiple sclerosis. pregnancy in multiple sclerosis group","volume":"339","author":"Confavreux","year":"1998","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2019.101483_bib0002","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1177\/1352458507077896","article-title":"Pregnancy in multiple sclerosis patients treated with immunomodulators prior to or during part of the pregnancy: a descriptive study in the spanish population","volume":"13","author":"De Las Heras","year":"2007","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2019.101483_bib0003","doi-asserted-by":"crossref","first-page":"e840","DOI":"10.1212\/WNL.0000000000005065","article-title":"Relapse occurrence in women with multiple sclerosis during pregnancy in the new treatment era","volume":"90","author":"Alroughani","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2019.101483_bib0004","first-page":"e832","article-title":"Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: II: maternal risks","volume":"90","author":"Portaccio","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2019.101483_bib0005","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1001\/archneurol.2010.257","article-title":"Immune reconstitution inflammatory syndrome in patients with multiple sclerosis following cessation of natalizumab therapy","volume":"68","author":"Miravalle","year":"2011","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.msard.2019.101483_bib0006","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1007\/s00415-014-7325-8","article-title":"Recurrence or rebound of clinical relapses after discontinuation of natalizumab therapy in highly active MS patients","volume":"261","author":"Sorensen","year":"2014","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2019.101483_bib0007","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1177\/1352458514549401","article-title":"Significant clinical worsening after natalizumab withdrawal: predictive factors","volume":"21","author":"Vidal-Jordana","year":"2015","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2019.101483_bib0008","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/ana.22366","article-title":"Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria","volume":"69","author":"Polman","year":"2011","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.msard.2019.101483_bib0009","doi-asserted-by":"crossref","first-page":"e109","DOI":"10.1111\/ene.12195","article-title":"Rebound of disease activity during pregnancy after withdrawal of fingolimod","volume":"20","author":"Sempere","year":"2013","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.msard.2019.101483_bib0010","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1001\/jamaneurol.2016.0826","article-title":"Rebound syndrome in patients with multiple sclerosis after cessation of fingolimod treatment","volume":"73","author":"Hatcher","year":"2016","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.msard.2019.101483_bib0011","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.msard.2016.11.003","article-title":"Severe rebound after withdrawal of fingolimod treatment in patients with multiple sclerosis","volume":"11","author":"G\u00fcnd\u00fcz","year":"2017","journal-title":"Mult. Scler. Relat. Disord"},{"key":"10.1016\/j.msard.2019.101483_bib0012","doi-asserted-by":"crossref","first-page":"e377","DOI":"10.1212\/NXI.0000000000000377","article-title":"Dramatic rebounds of MS during pregnancy following fingolimod withdrawal","volume":"4","author":"Novi","year":"2017","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.msard.2019.101483_bib0013","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.msard.2018.07.001","article-title":"Tumefactive multiple sclerosis lesions associated with fingolimod treatment: report of 5 cases","volume":"25","author":"S\u00e1nchez","year":"2018","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2019.101483_bib0014","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1111\/ene.13694","article-title":"Clinical activity after fingolimod cessation: disease reactivation or rebound?","volume":"25","author":"Frau","year":"2018","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.msard.2019.101483_bib0015","article-title":"A comparison of multiple sclerosis disease activity after discontinuation of fingolimod and placebo","volume":"3","author":"Vermersch","year":"2017","journal-title":"Mult. Scler. J. Exp. Transl. Clin."},{"key":"10.1016\/j.msard.2019.101483_bib0016","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1097\/NRL.0000000000000154","article-title":"Factors predictive of severe multiple sclerosis disease reactivation after fingolimod cessation","volume":"23","author":"Uygunoglu","year":"2018","journal-title":"Neurologist"},{"key":"10.1016\/j.msard.2019.101483_bib0017","doi-asserted-by":"crossref","first-page":"2647","DOI":"10.2169\/internalmedicine.0793-18","article-title":"Disease exacerbation after the cessation of fingolimod treatment in japanese patients with multiple sclerosis","volume":"57","author":"Sato","year":"2018","journal-title":"Intern. Med."},{"key":"10.1016\/j.msard.2019.101483_bib0018","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.bbi.2015.06.019","article-title":"Dysregulation of sphingosine 1 phosphate receptor-1 (S1P1) signaling and regulatory lymphocyte-dependent immunosuppression in a model of post-fingolimod MS rebound","volume":"50","author":"Cavone","year":"2015","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.msard.2019.101483_bib0019","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1177\/1352458517713147","article-title":"Reconstitution of the peripheral immune repertoire following withdrawal of fingolimod","volume":"23","author":"Ghadiri","year":"2017","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2019.101483_bib0020","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1080\/14740338.2017.1311321","article-title":"Treatment of multiple sclerosis during pregnancy - safety considerations","volume":"16","author":"Th\u00f6ne","year":"2017","journal-title":"Expert Opin. Drug. Saf."},{"key":"10.1016\/j.msard.2019.101483_bib0021","doi-asserted-by":"crossref","first-page":"e320","DOI":"10.1212\/NXI.0000000000000320","article-title":"An observational study of alemtuzumab following fingolimod for multiple sclerosis","volume":"4","author":"Willis","year":"2017","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034819304729?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034819304729?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T08:46:11Z","timestamp":1761900371000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034819304729"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":21,"alternative-id":["S2211034819304729"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2019.101483","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rebound of multiple sclerosis activity after fingolimod withdrawal due to planning pregnancy: Analysis of predisposing factors","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2019.101483","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101483"}}